336
Views
6
CrossRef citations to date
0
Altmetric
Research Article

A comparison of the therapeutic and reactivating efficacy of newly developed bispyridinium compounds (K206, K269) with currently available oximes against tabun in rats and mice

, , , &
Pages 776-780 | Received 06 Sep 2007, Accepted 30 Oct 2007, Published online: 20 Oct 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Kamil Kuca, Kamil Musilek, Daniel Jun, Miroslav Pohanka, Kallol Kumar Ghosh & Martina Hrabinova. (2010) Oxime K027: novel low-toxic candidate for the universal reactivator of nerve agent- and pesticide-inhibited acetylcholinesterase. Journal of Enzyme Inhibition and Medicinal Chemistry 25:4, pages 509-512.
Read now
Jiri Kassa, Jana Karasova, Jiri Bajgar, Kamil Kuca, Kamil Musilek & Irena Kopelikova. (2009) A comparison of the reactivating and therapeutic efficacy of newly developed bispyridinium oximes (K250, K251) with commonly used oximes against tabun in rats and mice. Journal of Enzyme Inhibition and Medicinal Chemistry 24:4, pages 1040-1044.
Read now

Articles from other publishers (4)

Yuan Liu, Xiaoli Zhou, Xiaofeng Wang, Qian Li & Dongfeng Yin. (2020) c(RGDyK)-mediated Pluronic-PBCA nanoparticles through the blood-brain barrier to enhance the treatment of central organophosphorus intoxication. Journal of Nanoparticle Research 22:11.
Crossref
Filip Caisberger, Jaroslav Pejchal, Jan Misik, Jiri Kassa, Martin Valis & Kamil Kuca. (2018) The benefit of combinations of oximes for the ability of antidotal treatment to counteract sarin-induced brain damage in rats. BMC Pharmacology and Toxicology 19:1.
Crossref
Halil Gökce & Semiha Bahçeli. (2011) A study on quantum chemical calculations of 3-, 4-nitrobenzaldehyde oximes. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 79:5, pages 1783-1793.
Crossref
Kamil Kuca, Kamil Musilek, Miroslav Pohanka, Vlastimil Dohnal & Jiri Patocka. (2009) REACTIVATION POTENCY OF THE ACETYLCHOLINESTERASE REACTIVATOR OBIDOXIME IS LIMITED. Biomedical Papers 153:4, pages 259-262.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.